These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 16440422)

  • 1. Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: a comparison between two different daily doses of lansoprazole.
    Baldi F; Cappiello R; Cavoli C; Ghersi S; Torresan F; Roda E
    World J Gastroenterol; 2006 Jan; 12(1):82-8. PubMed ID: 16440422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment.
    Poe RH; Kallay MC
    Chest; 2003 Mar; 123(3):679-84. PubMed ID: 12628862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.
    Newton M; Burnham WR; Kamm MA
    Eur J Gastroenterol Hepatol; 1998 Sep; 10(9):753-8. PubMed ID: 9831269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole.
    Hatlebakk JG; Berstad A
    Aliment Pharmacol Ther; 1997 Dec; 11(6):1093-9. PubMed ID: 9663835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On-demand PPI requirements in patients with endoscopy-negative GERD.
    Juul-Hansen P; Rydning A
    J Clin Gastroenterol; 2004 Oct; 38(9):746-9. PubMed ID: 15365398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison.
    Frazzoni M; De Micheli E; Grisendi A; Savarino V
    Aliment Pharmacol Ther; 2002 Jan; 16(1):35-9. PubMed ID: 11856076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children.
    Tolia V; Ferry G; Gunasekaran T; Huang B; Keith R; Book L
    J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S308-18. PubMed ID: 12607791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
    Janczewska I; Sagar M; Sjöstedt S; Hammarlund B; Iwarzon M; Seensalu R
    Scand J Gastroenterol; 1998 Dec; 33(12):1239-43. PubMed ID: 9930385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.
    Park W; Hicks DM; Khandwala F; Richter JE; Abelson TI; Milstein C; Vaezi MF
    Laryngoscope; 2005 Jul; 115(7):1230-8. PubMed ID: 15995512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison.
    Frazzoni M; Grisendi A; Lanzani A; Melotti G; De Micheli E
    Dig Liver Dis; 2002 Feb; 34(2):99-104. PubMed ID: 11926567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    Miner P; Katz PO; Chen Y; Sostek M
    Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton pump inhibitors or surgery for gastro-oesophageal reflux disease.
    Hinder RA
    Dig Liver Dis; 2002 Feb; 34(2):95-6. PubMed ID: 11926565
    [No Abstract]   [Full Text] [Related]  

  • 13. Endoscopy-negative reflux disease: what is the value of a proton-pump inhibitor test in everyday clinical practice?
    Juul-Hansen P; Rydning A
    Scand J Gastroenterol; 2003 Dec; 38(12):1200-3. PubMed ID: 14750637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy.
    Nzeako UC; Murray JA
    Aliment Pharmacol Ther; 2002 Jul; 16(7):1309-16. PubMed ID: 12144581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children.
    Tolia V; Fitzgerald J; Hassall E; Huang B; Pilmer B; Kane R
    J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S300-7. PubMed ID: 12607790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of symptoms in step-down therapy of gastroesophageal reflux disease.
    Mine S; Iida T; Tabata T; Kishikawa H; Tanaka Y
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1365-70. PubMed ID: 16105122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms.
    Littner MR; Leung FW; Ballard ED; Huang B; Samra NK;
    Chest; 2005 Sep; 128(3):1128-35. PubMed ID: 16162697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.
    Freston JW
    Am J Med; 2004 Sep; 117 Suppl 5A():14S-22S. PubMed ID: 15478848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression.
    Frazzoni M; De Micheli E; Grisendi A; Savarino V
    Aliment Pharmacol Ther; 2002 May; 16(5):881-6. PubMed ID: 11966495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lansoprazole: in the management of gastroesophageal reflux disease in children.
    Scott LJ
    Paediatr Drugs; 2003; 5(1):57-61; discussion 62. PubMed ID: 12513106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.